Trial Profile
Gallium-68 PSMA-11 PET Imaging in Patients With Biochemical Recurrence
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Aug 2022
Price :
$35
*
At a glance
- Drugs Gallium (68Ga) gozetotide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use
- 04 Jul 2022 Results from NCT02940262; NCT03353740, NCT03396874, retrospectively evaluating disease extent in men stratified by EAU BCR risk groups or biochemical persistence ,presented at the 37th Congress of the European Association of Urology
- 06 Oct 2020 Status changed from active, no longer recruiting to completed.
- 15 Feb 2020 Results, assessing the impact of 68Ga-PSMA-11 PET/CT on management of biochemically recurrent prostate cancer in a large prospective cohort, presented at the 2020 Genitourinary Cancers Symposium